| pubmed-article:21299548 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21299548 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21299548 | lifeskim:mentions | umls-concept:C0320385 | lld:lifeskim |
| pubmed-article:21299548 | lifeskim:mentions | umls-concept:C0666743 | lld:lifeskim |
| pubmed-article:21299548 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:21299548 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:21299548 | pubmed:dateCreated | 2011-2-8 | lld:pubmed |
| pubmed-article:21299548 | pubmed:abstractText | Infliximab, a chimeric antitumour necrosis factor (TNF) monoclonal antibody, has become an established effective therapy for inflammatory rheumatic disease. However, TNF is a critical factor in host defence, and the suppression of its biological activity may be associated with the increased risk of opportunistic infections. The frequent use of infliximab in clinical practice has identified Pneumocystis jirovecii pneumonia (PcP) as a serious complication. Individuals colonized with Pneumocystis may be at high risk of development of PcP when they have undergone immunosuppression. Hence, we addressed the question of the frequency of Pneumocystis colonization among patients treated with infliximab. | lld:pubmed |
| pubmed-article:21299548 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21299548 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21299548 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21299548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21299548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21299548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21299548 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21299548 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:21299548 | pubmed:issn | 1365-2362 | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:CalderónEnriq... | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:GoldaniLucian... | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:RespaldizaNie... | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:MedranoFranci... | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:de la... | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:VarelaJosé... | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:WissmannGusta... | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:Montes-CanoMa... | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:FriazaVicente... | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:MorillaRubénR | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:Martín-Garrid... | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:PovedanoJuanJ | lld:pubmed |
| pubmed-article:21299548 | pubmed:author | pubmed-author:Praena-Fernán... | lld:pubmed |
| pubmed-article:21299548 | pubmed:copyrightInfo | © 2010 The Authors. European Journal of Clinical Investigation © 2010 Stichting European Society for Clinical Investigation Journal Foundation. | lld:pubmed |
| pubmed-article:21299548 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21299548 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:21299548 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21299548 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21299548 | pubmed:pagination | 343-8 | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:meshHeading | pubmed-meshheading:21299548... | lld:pubmed |
| pubmed-article:21299548 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21299548 | pubmed:articleTitle | Pneumocystis jirovecii colonization in patients treated with infliximab. | lld:pubmed |
| pubmed-article:21299548 | pubmed:affiliation | Pneumocystis Study Group, Infectology Unit, Clinical Hospital of Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. | lld:pubmed |
| pubmed-article:21299548 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21299548 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
